Zevra Therapeutics (FRA:1GDA) ROE % Adjusted to Book Value : -23.69% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics ROE % Adjusted to Book Value?

Zevra Therapeutics's ROE % for the quarter that ended in Mar. 2024 was -120.36%. Zevra Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was 5.08. Zevra Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -23.69%.

Zevra Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Zevra Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics ROE % Adjusted to Book Value Chart

Zevra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-10.72

-13.51

-16.88

Zevra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-28.59	-11.94	-31.42	-23.64	-23.69

Competitive Comparison of Zevra Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Zevra Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zevra Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's ROE % Adjusted to Book Value falls into.

Zevra Therapeutics ROE % Adjusted to Book Value Calculation

Zevra Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-66.16%	/	3.92
	=	-16.88%

Zevra Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-120.36%	/	5.08
	=	-23.69%

Zevra Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (FRA:1GDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ZVRA:USA 1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines